Alpha Cognition Announces Executive Shake-up & Drug Approval
Company Announcements

Alpha Cognition Announces Executive Shake-up & Drug Approval

Story Highlights

Alpha Cognition Inc (TSE:ACOG) has released an update.

Alpha Cognition Inc., a biopharmaceutical firm focusing on neurodegenerative diseases, has announced the resignation of CFO Don Kalkofen and the interim appointment of Jay Yoo, an experienced CPA and CFA. The company has recently achieved significant milestones, including the approval of their Alzheimer’s treatment ZUNVEYL, and is preparing for its early 2025 launch.

For further insights into TSE:ACOG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskAlpha Cognition Plans Nasdaq Listing and $25M Offering
TipRanks Canadian Auto-Generated NewsdeskAlpha Cognition Inc. Appoints New Finance VP
TipRanks Canadian Auto-Generated NewsdeskAlpha Cognition Secures U.S. Patent for Alzheimer’s Drug
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App